Enzo Biochem Reports Increased Fiscal Second Quarter Results
NEW YORK--(BUSINESS WIRE)--Enzo Biochem, Inc. (NYSE:ENZ) today reported results for the second fiscal quarter and fiscal first half ended January 31, 2016, led by strong gains at Enzo Clinical Labs reflecting increased molecular diagnostic testing demand.
Among the quarter’s highlights:
• Revenues of $24.6 million grew 6% year over year, including a 19% increase at Enzo Clinical Labs
Among the quarter’s highlights:
• Revenues of $24.6 million grew 6% year over year, including a 19% increase at Enzo Clinical Labs